The $99 Hearing Aid Is Here — What Four Years of OTC Competition Actually Changed

In August 2022 the FDA finalized a rule that few consumer categories ever get: it legalized competition. Over-the-counter hearing aids reached shelves that October, letting adults with perceived mild to moderate hearing loss buy without an exam, a prescription or a fitting. Four years later the price effect is unmistakable — devices like Nebroo's Pro 3.0 at $99 now sit where four-figure prescriptions used to stand alone. It's worth being precise about what that changed, and about what it structurally didn't.

The problem the rule was aimed at

Hearing loss ranks among the most common chronic health conditions, and the treatment gap has long been enormous: by widely cited estimates, the large majority of adults who could benefit from hearing aids don't use them. Surveys consistently put cost and friction at the top of the reasons — a professional channel meant an appointment, a wait, a fitting, and a price that for many simply ended the conversation. The OTC category was a direct attempt to remove all four barriers at once for the people whose loss was mild enough that a preset device could plausibly serve them.

What competition actually delivered

Price, decisively. Sales pages in the category now routinely contrast their own figure against averages for prescription pairs running into the thousands — Nebroo's page cites $4,672 — and those comparisons are directionally consistent with published US pricing. Consumer-electronics manufacturing did the rest: the signal processing that shapes sound by frequency band, compresses dynamic range and suppresses steady noise is no longer exotic hardware. Combine cheap processing with a direct sales channel and $99 stops being surprising.

Access followed price. For the person who has spent a decade asking people to repeat themselves because a $4,000 quote ended the discussion, a $99 device behind a long return window is a genuinely different proposition — and doing something is meaningfully better than the years of doing nothing that cost created.

What it structurally didn't change

The clinical line held, because the rule drew it deliberately. OTC remains limited to adults 18+ with perceived mild to moderate hearing loss. Severe loss and minors remain prescription. The FDA's red-flag conditions — sudden hearing change, one-sided loss, pain, drainage, dizziness, one-sided ringing — still mean see a doctor rather than buy a device, because those symptoms can reflect causes that amplification doesn't address and delay doesn't help.

And no price collapse turns a preset into a measurement. A professionally fitted aid is programmed to your audiogram — your thresholds at each frequency, in each ear — and adjusted over follow-ups. A self-fitted device offers preset profiles and your own perception. For typical mild-to-moderate loss that trade works, which is the premise of the category; the further your hearing departs from typical, the more the measurement is worth. Our explainer on how these devices process sound covers exactly where that line sits.

The house rules for buying at the cheap end

Three checks, none glamorous, all decisive. Check the label: «OTC hearing aid» is an FDA-regulated medical device with required warnings and output limits; «hearing amplifier» or PSAP is an unregulated product intended for people without hearing loss. They share shelves and price points and are not the same purchase. Check yourself against the red flags before shopping at all. And check the return window — the FDA requires packaging to state a return policy but doesn't require one to exist, which makes a long guarantee (Nebroo declares 120 days) the most valuable commercial term in the category, because hearing benefit can only be judged by wearing the thing in your own life for weeks.

The full decision path is in our OTC hearing aid buying guide, and the product-level assessment is in our Nebroo Pro 3.0 review. The live board tracks where the category moves next as competition continues.